News 2020-05-13
Porton Shanghai Formulation R&D Center Launched Construction
Shanghai, China, May 13, 2020 - Porton Pharmatech Co. ,Ltd. (Porton Pharmatech), a subsidiary of Porton Pharma Solutions Ltd. (Porton, Stock Code: 300363), today announced the commencement of construction of its Shanghai R&D Center, which would be Porton’s third formulation lab site that has been constructed since 2019. It has previously started design and construction of two other formulation labs based in Chongqing, China and New Jersey，USA.
Others
More
News 2025-08-04
Porton Newsletter - July 2025 Recap
Technical Enabling Services & Solutions Company Events Marketing Activities
News 2025-07-31
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.
